CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01911 CR HOLDINGS

Market Closed 05-22 16:08:22

3.610

+0.080

+2.27%

High3.670	Low3.460	Vol550.40K
Open3.530	D1 Closing3.530	Amplitude5.95%
Mkt Cap2.07B	Tradable Cap2.07B	Total Shares573.00M
T/O1.98M	T/O Rate0.10%	Tradable Shares573.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01911","market":"HK","secType":"STK","nameCN":"CR HOLDINGS","latestPrice":3.61,"timestamp":1779437302003,"preClose":3.53,"halted":0,"volume":550400,"delay":0,"changeRate":0.02266288951841362,"floatShares":573000000,"shares":573000000,"eps":0.21898019949382166,"marketStatus":"Market Closed","change":0.08,"latestTime":"05-22 16:08:22","open":3.53,"high":3.67,"low":3.46,"amount":1982748,"amplitude":0.05949,"askPrice":3.61,"askSize":30000,"bidPrice":3.56,"bidSize":400,"shortable":3,"etf":0,"ttmEps":0.2258953636883634,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779759000000},"marketStatusCode":7,"adr":0,"listingDate":1537977600000,"exchange":"SEHK","adjPreClose":3.53,"openAndCloseTimeList":[[1779413400000,1779422400000],[1779426000000,1779436800000]],"volumeRatio":0.3678701760385015,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01911","defaultTab":"news","newsList":[{"id":"2637363348","title":"Innovent reports early NSCLC data for IBI363 plus chemotherapy in Phase 1 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363348","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637363348?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:50","pubTimestamp":1779407451,"startTime":"0","endTime":"0","summary":"Innovent Biologics flagged preliminary proof-of-concept results for its IBI363 immunotherapy candidate combined with platinum-based chemotherapy as a first-line treatment for advanced non-small cell lung cancer, with more detailed data scheduled for presentation at the 2026 ASCO Annual Meeting.Early findings pointed to strong tumor response signals in patients with low or negative PD-L1 expression, a segment where current checkpoint-based regimens can deliver weaker benefit.The company highlighted a dosing approach intended to support longer treatment duration, citing a tolerability profile it characterized as manageable in the preferred regimen.A second-stage randomized head-to-head trial is ongoing, testing IBI363 with chemotherapy against pembrolizumab with chemotherapy in first-line advanced NSCLC across all PD-L1 expression levels.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL58yPkc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","LU1969619763.USD","01911","LU0502904849.HKD","BK1583","01801","LU2242644610.SGD","LU2097828474.EUR","LU2097828805.USD","LU0455707207.USD","LU2328871848.SGD","BK1589","LU2097828631.EUR","BK1147","HK0000165453.HKD","LU2097828714.EUR","BK1161","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636007475","title":"Innovent reports Phase Ib asthma trial data for IBI3002 IL-4Rα/TSLP antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2636007475","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636007475?lang=en_us&edition=fundamental","pubTime":"2026-05-19 08:00","pubTimestamp":1779148845,"startTime":"0","endTime":"0","summary":"Innovent Biologics will present clinical Phase Ib results for its IBI3002 bispecific asthma antibody at the American Thoracic Society meeting on May 17-20, 2026.The single-dose study in mild-to-moderate asthma showed favorable safety and tolerability, with signals of improved lung function and reduced markers linked to type 2 airway inflammation versus placebo.Preclinical data for two other bispecific programs, IBI3038 for fibrosis-related autoimmune disease and IBI3031 for thyroid eye disease, were presented at ATS and ARVO in May 2026, supporting plans to move both candidates into clinical development later in 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL69TqKN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU2097828557.USD","LU2097828631.EUR","BK1161","01911","HK0000165453.HKD","LU0455707207.USD","LU2097828714.EUR","LU2097828805.USD","LU2328871848.SGD","LU2242644610.SGD","BK1583","LU2488822045.USD","LU0502904849.HKD","BK1589","BK1147","01801","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635922153","title":"Innovent presents Phase 3 mazdutide obesity, diabetes trial results at ADA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635922153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635922153?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:00","pubTimestamp":1778630428,"startTime":"0","endTime":"0","summary":"Innovent Biologics flagged new clinical and preclinical readouts for obesity candidate mazdutide, set for presentation at 2026 American Diabetes Association Scientific Sessions in New Orleans on June 5-8.Future presentations include late-stage results comparing mazdutide with semaglutide in Chinese adults with type 2 diabetes and obesity, plus Phase 3 data in adults with obesity, positioning the drug on weight loss, glucose control, and broader metabolic benefits.Additional data due at the meeting include early-stage safety and pharmacokinetic findings in adolescents with obesity, extending the program into younger patients.Pipeline disclosures scheduled for posters include early clinical results for daily oral GLP-1 small molecule IBI3032, preclinical efficacy for amylin analog IBI3040, and preclinical durability signals for INHBE-targeting siRNA IBI3046, underscoring a push toward oral dosing, tolerability, and longer-lasting weight control.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL7YWSn0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","BK1161","BK1583","BK1589","LU1969619763.USD","LU2097828474.EUR","LU2328871848.SGD","HK0000165453.HKD","LU0455707207.USD","LU2097828557.USD","LU0502904849.HKD","LU2488822045.USD","LU2242644610.SGD","LU2097828631.EUR","LU2097828714.EUR","01911","LU2097828805.USD","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634422172","title":"Innovent says NMPA grants IBI363 breakthrough therapy status for MSS colorectal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2634422172","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634422172?lang=en_us&edition=fundamental","pubTime":"2026-05-11 08:00","pubTimestamp":1778457626,"startTime":"0","endTime":"0","summary":"Innovent received China NMPA CDE Breakthrough Therapy Designation for IBI363 with bevacizumab in advanced MSS/pMMR metastatic colorectal cancer in patients who failed at least two prior treatment lines.Phase III trial in China set to start soon for this indication.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL7bv204:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU2097828714.EUR","01911","BK1161","LU1969619763.USD","BK1589","LU2488822045.USD","BK1583","LU2097828557.USD","LU2242644610.SGD","HK0000165453.HKD","01801","LU0502904849.HKD","LU0455707207.USD","LU2097828805.USD","BK1147","LU2328871848.SGD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165993761","title":"CR Holdings Keeps Share Capital Steady in April 2026; 10.34 Million Options Remain Outstanding","url":"https://stock-news.laohu8.com/highlight/detail?id=1165993761","media":"Bulletin Express","labels":["SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165993761?lang=en_us&edition=fundamental","pubTime":"2026-05-06 16:03","pubTimestamp":1778054599,"startTime":"0","endTime":"0","summary":"China Renaissance Holdings Limited (CR Holdings) submitted its Monthly Return for the period ended 30 April 2026, confirming that the group’s share capital structure was unchanged during the month. •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145419433","title":"CR HOLDINGS 2025年收入与投资收益总额约11.98亿元，股东应占净利润约1.01亿元，成功扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1145419433","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145419433?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:47","pubTimestamp":1777513640,"startTime":"0","endTime":"0","summary":"CR...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CR HOLDINGS 2025年收入与投资收益总额约11.98亿元，股东应占净利润约1.01亿元，成功扭亏为盈","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631748905","title":"China Renaissance publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631748905","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631748905?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:34","pubTimestamp":1777512840,"startTime":"0","endTime":"0","summary":"China Renaissance issued its 2025 annual report, highlighting a return to profitability as investment management drove results.Realized carried interest rose sharply to RMB 524.1 million, supported by exits that distributed about RMB 2.5 billion to limited partners.Investment banking posted a rebound in deal activity, with aggregate transaction value reaching about RMB 23.2 billion, led by private equity financing in AI-related sectors.CR Securities narrowed operating losses, helped by stronger retail and brokerage momentum as Duoduojin App users climbed to about 570,000.Group invested about RMB 308.3 million in distressed assets, targeting full capital recovery within about three years or less.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL2VNlvH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631573972","title":"Innovent Q1 product revenue tops RMB 3.8 billion, up over 50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631573972","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631573972?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:30","pubTimestamp":1777505450,"startTime":"0","endTime":"0","summary":"Innovent reported first-quarter 2026 total product revenue of over RMB 3.8 billion.Revenue rose more than 50% year over year.Growth reflected rapid uptake of five TKI therapies added to NRDL, supported by strong performance from mazdutide, SINTBILO, SYCUME.Company highlighted plans to advance three assets into or toward global MRCT Phase 3 trials: IBI363, IBI343, IBI324.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLtf2BQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","01911","BK1161","LU2097828631.EUR","LU0502904849.HKD","LU1969619763.USD","LU0455707207.USD","BK1589","BK1147","BK1583","HK0000165453.HKD","LU2242644610.SGD","LU2328871848.SGD","01801","LU2488822045.USD","LU2097828714.EUR","LU2097828557.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630864845","title":"Innovent Biologics releases 2025 ESG report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630864845","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630864845?lang=en_us&edition=fundamental","pubTime":"2026-04-28 23:07","pubTimestamp":1777388846,"startTime":"0","endTime":"0","summary":"Innovent Biologics released its 2025 environmental, social, governance report covering performance for period from Jan. 1, 2025 to Dec. 31, 2025.MSCI ESG rating held at AAA, placing company among top performers in global biotechnology peer group.Anti-corruption controls tightened, with 100% of staff and directors completing business ethics training.Environmental intensity metrics improved versus 2024, with energy use per unit down 28% and freshwater use per unit down 42%.Patient access initiatives expanded, with patient assistance programs reaching over 238,000 patients and donated medicines valued at RMB 4 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLgHmX0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","LU2488822045.USD","LU2328871848.SGD","01911","LU2097828805.USD","HK0000165453.HKD","LU0455707207.USD","LU2097828714.EUR","BK1583","LU2242644610.SGD","01801","LU2097828557.USD","LU0502904849.HKD","BK1589","LU2097828474.EUR","BK1161","LU1969619763.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630869165","title":"Innovent Biologics publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630869165","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630869165?lang=en_us&edition=fundamental","pubTime":"2026-04-28 23:00","pubTimestamp":1777388437,"startTime":"0","endTime":"0","summary":"Innovent annual report for year ended Dec. 31, 2025 flagged a shift to sustained profitability, supported by rapid commercial scale-up and operating leverage.Commercial portfolio expanded to 18 marketed products, with oncology remaining core franchise while general biomedicine emerged as second growth engine led by Mazdutide, SYCUME, SINTBILO.Global strategy accelerated with three lead assets positioned for global Phase 3 programs, led by IBI363 in lung cancer, IBI343 in gastrointestinal cancers, IBI324 in retinal disease.Partnership activity broadened with Takeda on IBI363 and IBI343, with additional out-licensing to Roche for IBI3009 to push pipeline into overseas development.Manufacturing footprint scaled with 140,000 liters of capacity in operation, supporting expanding product mix including antibody and ADC programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLbFLycb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","BK1161","BK1583","LU2097828557.USD","LU2328871848.SGD","BK1589","LU2488822045.USD","LU0455707207.USD","HK0000165453.HKD","01911","LU1969619763.USD","LU2242644610.SGD","LU2097828474.EUR","01801","LU2097828714.EUR","BK1147","LU0502904849.HKD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629061195","title":"Innovent advances IBI363 into phase 3 MarsLight-11 trial in squamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2629061195","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629061195?lang=en_us&edition=fundamental","pubTime":"2026-04-22 08:00","pubTimestamp":1776816038,"startTime":"0","endTime":"0","summary":"Innovent flagged new clinical data for IBI363, its PD-1/IL-2α-biased bispecific fusion protein, for presentation at ASCO 2026 in Chicago on May 29 to June 2.Presentations will cover proof-of-concept results in non-small cell lung cancer across immunotherapy-resistant patients and first-line treatment, positioning IBI363 as a potential new option in a high-need setting.Innovent has moved IBI363 into multiregional pivotal development for immunotherapy-resistant NSCLC, marking a step toward late-stage registration strategy.ASCO 2026 program also includes a phase 3 trial design disclosure for MarsLight-11, which will compare IBI363 with docetaxel in previously treated squamous NSCLC.Separate ASCO 2026 abstracts will present additional clinical studies involving TYVYT  across multiple tumor types, supporting lifecycle expansion efforts.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL66fCVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","LU2097828474.EUR","LU0455707207.USD","LU0502904849.HKD","LU2097828557.USD","LU2242644610.SGD","BK1147","LU2488822045.USD","LU2097828714.EUR","LU2097828631.EUR","BK1161","01801","LU1969619763.USD","LU2097828805.USD","HK0000165453.HKD","BK1589","LU2328871848.SGD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626159507","title":"Innovent presents preclinical data on IBI3055 at Immune Resetting Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626159507","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626159507?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:00","pubTimestamp":1775779217,"startTime":"0","endTime":"0","summary":"Innovent presented at 2026 Immune Resetting: B-Cell Mediated & Beyond Summit in Boston on April 9, 2026.Oral presentation disclosed preclinical data for IBI3055, a CD19/BCMA/CD3 tri-specific T-cell engager that depleted B cells and plasma cells in animal studies while showing favorable tolerability in non-human primates.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL1Gg9NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0502904849.HKD","01801","BK1147","01911","LU2097828474.EUR","LU2242644610.SGD","LU2328871848.SGD","LU2488822045.USD","LU2097828714.EUR","BK1583","LU2097828557.USD","BK1589","HK0000165453.HKD","LU1969619763.USD","LU2097828805.USD","LU2097828631.EUR","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624548093","title":"China Renaissance Holdings SEHK 1911 Return To Profit Tests Longstanding Bearish Earnings Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2624548093","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624548093?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:31","pubTimestamp":1775050289,"startTime":"0","endTime":"0","summary":"China Renaissance Holdings (SEHK:1911) has reported FY 2025 first half revenue of C¥509 million and basic EPS of C¥0.13, with investors focused on how this compares with the recent trailing 12 month EPS of C¥0.19. The company has seen revenue move from C¥351.8 million and C¥471.7 million in the first and second halves of 2024 to the current C¥509 million, while EPS has shifted from losses of C¥0.15 and C¥0.20 per share in those periods to a positive C¥0.13. This sets the stage for a closer...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/china-renaissance-holdings-sehk-1911-return-to-profit-tests","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/china-renaissance-holdings-sehk-1911-return-to-profit-tests","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01911","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112329027","title":"CR Holdings Posts Stable Share Capital in March; 573.35 Million Shares Outstanding, No New Issuances","url":"https://stock-news.laohu8.com/highlight/detail?id=1112329027","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112329027?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:03","pubTimestamp":1775037808,"startTime":"0","endTime":"0","summary":"China Renaissance Holdings Limited (CR Holdings) reported no changes to its share capital structure for the month ended 31 March 2026, according to the company’s latest monthly return filed with Hong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623320255","title":"Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623320255","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623320255?lang=en_us&edition=fundamental","pubTime":"2026-03-31 08:00","pubTimestamp":1774915229,"startTime":"0","endTime":"0","summary":"Innovent partner Ollin Biosciences released final 20-week data from Phase 1b JADE head-to-head study of OLN324  versus Roche’s Vabysmo in diabetic macular edema or wet age-related macular degeneration.Results showed OLN324 delivered stronger anatomic improvements in diabetic macular edema, with vision gains that held up through follow-up.Wet age-related macular degeneration data showed comparable fluid control, with a widening edge in vision outcomes for OLN324 by study end.Newly available anatomic analyses indicated faster, greater, more durable reductions in pigment epithelial detachments versus Vabysmo.Full data set is expected to be presented at upcoming medical meetings, with global Phase 3 studies planned for 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL9qWvky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU0502904849.HKD","LU2328871848.SGD","LU2097828557.USD","01911","BK1583","LU2097828631.EUR","BK1161","LU0455707207.USD","LU2242644610.SGD","LU1969619763.USD","BK1147","LU2488822045.USD","LU2097828714.EUR","BK1589","01801","LU2097828805.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623327692","title":"Innovent Biologics grants 10.2 million restricted shares under 2024 share scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2623327692","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623327692?lang=en_us&edition=fundamental","pubTime":"2026-03-31 07:02","pubTimestamp":1774911746,"startTime":"0","endTime":"0","summary":"Innovent Biologics granted 1,935,642 share options under 2024 Share Scheme, priced at HK$86.10 per share.Company also granted 10,241,272 restricted shares with nil consideration, implying market value of about HK$880 million at HK$86.10 per share.Directors received 706,549 options; chairman and CEO De-Chao Michael Yu received 486,000.Directors received 1,847,721 restricted shares; Yu received 1,377,000.Options run for 10 years from March 30, 2026; most employee awards vest 75% on March 30, 2029, with remaining 25% on March 30, 2030.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL4tPwH9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","LU1969619763.USD","01911","LU0502904849.HKD","BK1583","01801","LU2242644610.SGD","LU2097828474.EUR","LU2097828805.USD","LU0455707207.USD","LU2328871848.SGD","BK1589","LU2097828631.EUR","BK1147","HK0000165453.HKD","LU2097828714.EUR","BK1161","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623742319","title":"BRIEF-China Renaissance Logs FY Profit Attributable RMB101.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623742319","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623742319?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:54","pubTimestamp":1774868087,"startTime":"0","endTime":"0","summary":"BRIEF-China Renaissance Logs FY Profit Attributable RMB101.4 MlnMarch 30 (Reuters) - China Renaissance Holdings Ltd 1911.HK:FY PROFIT ATTRIBUTABLE RMB101.4 MILLIONFY TOTAL REVENUE RMB1.07 BILLIONFurther company coverage: 1911.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I0JM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","01911"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109659883","title":"CR HOLDINGS (01911) Reports Annual Results: Turns to Profit with RMB 101 Million Attributable to Owners","url":"https://stock-news.laohu8.com/highlight/detail?id=1109659883","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109659883?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:38","pubTimestamp":1774863526,"startTime":"0","endTime":"0","summary":"CR HOLDINGS (01911) announced its annual results for the period ended December 31, 2025. The Group recorded revenue of RMB 1.066 billion, an increase of 37.19% year-on-year. Profit attributable to...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","01911"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623339313","title":"China Renaissance - FY Total Revenue RMB1.07 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623339313","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623339313?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:26","pubTimestamp":1774862802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I0JM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1147","01911"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623313362","title":"China Renaissance FY25 profit attributable to owners swings to RMB 101m; revenue rises 37.2% to RMB 1.1bn","url":"https://stock-news.laohu8.com/highlight/detail?id=2623313362","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623313362?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:26","pubTimestamp":1774862772,"startTime":"0","endTime":"0","summary":"China Renaissance posted profit attributable to owners of RMB 101 million for FY2025, reversing a loss in prior year.Operating profit came in at RMB 133 million, swinging from an operating loss.Total revenue and net investment gains climbed 42.7% to RMB 1.2 billion, helped by realized carried interest of about RMB 524 million.Management expects to fully recover RMB 308 million invested in distressed assets within about three years or less.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Renaissance Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL1YzvBf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","BK1147"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinarenaissance.com","stockEarnings":[{"period":"1week","weight":0.0525},{"period":"1month","weight":-0.0055},{"period":"3month","weight":-0.2101},{"period":"6month","weight":-0.2618},{"period":"1year","weight":0.0873},{"period":"ytd","weight":-0.1259}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0153},{"period":"1year","weight":0.0876},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"China Renaissance Holdings Ltd is a holding company that is primarily engaged in providing investment banking and investment management services. The Company operates in four segments. Investment Banking segment provides early to late stage financial advisory and mergers and acquisitions advisory services, equity underwriting, sales, trading, brokerage, research services and structured financial services. Investment Management segment provides fund and asset management and manages its own investments in funds. China Renaissance (CR) Securities segment provides investment banking and asset management business. Others segment mainly includes wealth management business and investment and management of own funds.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.099096},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.014364},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.054298},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.054187},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.036319},{"month":6,"riseRate":1,"avgChangeRate":0.143061},{"month":7,"riseRate":0.4,"avgChangeRate":0.051599},{"month":8,"riseRate":0.6,"avgChangeRate":0.100699},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.131486},{"month":10,"riseRate":0,"avgChangeRate":-0.130048},{"month":11,"riseRate":0.285714,"avgChangeRate":0.027229},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.035994}],"exchange":"SEHK","name":"CR HOLDINGS","nameEN":"CR HOLDINGS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CR HOLDINGS(01911) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CR HOLDINGS,01911,CR HOLDINGS股票,CR HOLDINGS股票老虎,CR HOLDINGS股票老虎国际,CR HOLDINGS行情,CR HOLDINGS股票行情,CR HOLDINGS股价,CR HOLDINGS股市,CR HOLDINGS股票价格,CR HOLDINGS股票交易,CR HOLDINGS股票购买,CR HOLDINGS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CR HOLDINGS(01911) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}